Stifel Nicolaus Analysts Give Momenta Pharmaceuticals Inc. (MNTA) a $20.00 Price Target
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has been given a $20.00 target price by equities research analysts at Stifel Nicolaus in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 41.34% from the company’s previous close.
Several other research analysts have also recently commented on MNTA. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. JPMorgan Chase & Co. lowered their target price on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. Aegis began coverage on shares of Momenta Pharmaceuticals in a report on Tuesday, November 22nd. They set a “hold” rating and a $15.00 target price on the stock. Maxim Group reaffirmed a “sell” rating and set a $6.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Finally, Barclays PLC raised shares of Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $19.00 in a report on Tuesday, October 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Momenta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $16.10.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.71% on Tuesday, reaching $14.15. The company’s stock had a trading volume of 439,939 shares. Momenta Pharmaceuticals has a 12 month low of $7.86 and a 12 month high of $18.26. The firm’s market cap is $975.74 million. The firm’s 50 day moving average is $12.43 and its 200-day moving average is $11.73.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The company had revenue of $299.14 million for the quarter, compared to analysts’ expectations of $25.68 million. During the same period last year, the firm earned ($0.44) earnings per share. The business’s revenue for the quarter was up 2067.7% on a year-over-year basis. On average, equities research analysts anticipate that Momenta Pharmaceuticals will post ($1.16) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/29/momenta-pharmaceuticals-inc-mnta-stock-rating-reaffirmed-by-stifel-nicolaus.html.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the business’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $13.68, for a total transaction of $80,438.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 6.10% of the company’s stock.
Several hedge funds have recently bought and sold shares of MNTA. Pacad Investment Ltd. bought a new stake in Momenta Pharmaceuticals during the second quarter worth $103,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Jane Street Group LLC acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $109,000. Profund Advisors LLC acquired a new position in shares of Momenta Pharmaceuticals during the third quarter worth approximately $121,000. Finally, Mason Street Advisors LLC acquired a new position in shares of Momenta Pharmaceuticals during the second quarter worth approximately $134,000. 84.86% of the stock is currently owned by hedge funds and other institutional investors.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.